Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss

Introduction: Pharmacological options to address the imbalance between bone resorption and accrual in osteoporosis include anti-resorptive and osteoanabolic agents. Unique biologic pathways such as the Wnt/β-catenin pathway have been targeted in the quest for new emerging therapeutic strategies.

Areas covered: This review provides an overview of existing pharmacotherapy for osteoporosis in women and explore state-of–the-art and emerging therapies to prevent bone loss, with an emphasis on the mechanism of action, indications and side effects.

Expert opinion: Bisphosphonates appear to be a reliable and cost-effective option, whereas denosumab has introduced a simpler dosing regimen and may achieve a linear increase in bone mineral density (BMD) with no plateau being observed, along with continuous anti-fracture efficacy. Abaloparatide, a parathyroid-hormone-related peptide (PTHrP)-analogue, approved by the FDA in April 2017, constitutes the first new anabolic osteoporosis drug in the US for nearly 15 years and has also proven its anti-fracture efficacy. Romosozumab, a sclerostin inhibitor, which induces bone formation and suppresses bone resorption, has also been developed and shown a significant reduction in fracture incidence; however, concerns have arisen with regard to increased cardiovascular risk.     

Diffuse splenic and visceral hemangiomas complicated by chronic consumption coagulopathy

Abstract The case of a 7-year-old girl with a 2 year history of easy bruising associated with thrombocytopenia is reported. On admission she presented with ecchymoses, abdominal distention and splenomegaly. Hemostasis investigation revealed a consumption coagulopathy. Several radiological studies failed to confirm the diagnosis of diffuse splenic and visceral hemangiomatosis, which was eventually estasblished by an explorative laparotomy. Platelet count and the other coagulation abnormalities progressively returned to normal after splenectomy, although the remaining hemangiomas were extensive.     

Who Benefits from Portal Vein Resection during Pancreaticoduodenectomy for Pancreatic Cancer?

Portal vein resection during pancreaticoduodenectomy has recently experienced renewed interest. We describe our results with this procedure over a 20-year period. Among 88 consecutive pancreatectomies for cancer of head of the pancreas, 14 included en bloc removal of the portal vein. There was no hospital mortality. Only 21% were found to have histologically confirmed cancer invasion, and the remainder had inflammatory adherence. Two-year survival was 15% compared to 34% for patients who did not have portal vein resection. There were no 5-year survivors. We discuss our results in light of other recent reports.     

Pancreaticojejunostomy versus alternative treatment of the pancreatic stump after pancreaticoduodenectomy: a comparative analysis of early postoperative outcome

The operative management of the pancreatic stump after pancreaticoduodenectomy has been shown to be an important factor influencing the postoperative development of pancreatic fistula. Thus far, there is no ideal technique for reconstruction, and end-to-end pancreaticojejunostomy (PJS) represents the preferable method. Comparative analysis of early postoperative outcome was done between two groups of patients who underwent either end-to-end PJS or pancreatic remnant ligation (PRL) after pancreaticoduodenectomy. Between January 1997 and December 2001, 39 consecutive patients underwent pancreaticoduodenectomy at the 1st Department of Surgery, University of Athens Medical School. All operations were performed or supervised by two senior surgeons, and all patients underwent a Whipple's procedure. After pancreaticoduodenectomy, 23 patients underwent end-to-end PJS (PJS group), whereas the remaining 16 patients underwent PRL without pancreatic reconstruction (PRL group). We compared the two groups in terms of patients' characteristics, clinical presentation, serum laboratory values on admission, operative details, and postoperative course. The morbidity and mortality rates were 15.4% and 5.1%, respectively, for the whole series. In the PJS group, the morbidity rate was 8.7%, the pancreatic fistula formation rate was 4.3%, and the mortality rate was 4.3%. In the PRL group, the morbidity rate was 25%, the pancreatic fistula formation rate was 12.5%, and the mortality rate was 6.25%. These differences were not statistically significant. There were two deaths in the whole series (one in each group); however, none of the deaths were related to pancreatic fistula formation. Hospital stay was similar in both groups. Both PJS and PRL are valid surgical options that correlate with acceptable postoperative incidence of pancreatic fistula formation, morbidity, and mortality rates. Although PRL avoids the construction of the most risky anastomosis, the results of this study show that early postoperative results after PRL are not superior to PJS; therefore, the method should not be considered as the treatment of choice for the pancreatic stump after a Whipple's procedure. Meticulous surgical technique, surgical experience, and close postoperative care are essential for a successful outcome after this major abdominal operation.     

Rupture of right hepatic duct into hydatid cyst

Echinococcal disease can develop anywhere in the human body. The liver represents its most frequent location. Hepatic hydatid cysts may rupture into the biliary tract, thorax, peritoneum, viscera, digestive tract or skin. We report a rare case with rupture of the right hepatic duct into a hydatid cyst in a woman with known hydatid disease and choledocholithiasis. The increased intra-luminal pressure in the biliary tree caused the rupture into the adjacent hydatid cyst. The creation of the fistula between the right hepatic duct and the hydatid cyst decompressed the biliary tree, decreased the bilirubin levels and offered a temporary resolution of the obstructive jaundice. Rupture of a hydatid cyst into the biliary tree usually leads to biliary colic, cholangitis and jaundice. However, in case of obstructive jaundice due to choledocholithiasis, it is possible that the cyst may rupture by other way around while offering the patient a temporary relief from his symptoms.     

Vertigo during the Epley maneuver and success rate in patients with BPPV

To investigate whether reported vertigo during the Epley maneuver predicts therapeutic success in patients with benign paroxysmal positioning vertigo of the posterior semicircular canal (pc-BPPV). Fifty consecutive adult patients with pc-BPPV, based on a positive Dix–Hallpike test (DHT), were treated with the Epley maneuver and retested after 2 days. Patients were asked to report the presence of vertigo upon assuming each of the four positions of the maneuver. Thirty seven patients (74 %) were treated successfully in one session. Twenty out of 23 patients who reported vertigo at turning the head to the opposite side (2nd position) had a negative DHT on follow-up. These patients had a higher chance of a successful outcome compared to patients who did not report vertigo in the 2nd position (Odds ratio 5.3, 95 % CI: 1.3–22.2, p = 0.022). Report of vertigo at the other positions was not associated with the outcome. Report of vertigo at the second position of a single modified Epley maneuver is associated with therapeutic success.     

Oral manifestations in glycogen storage disease type 1b

Glycogen storage disease type 1b is a rare metabolic disorder which affects the transport system of glucose-6-phosphatase metabolism. As a result, hepatomegaly, failure to thrive, renal dysfunction and recurrent infections occur in affected patients. In this paper, the oral complications in three children with glycogen storage disease type 1b are discussed. Oral ulcers were a common rinding, probably due to severe neutropenia and impaired neutrophil migration which characterises the onset of this rare disorder.